$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
达拉非尼+曲美替尼:双靶获益明确,一线数据瞩目
2025-10-19 11:44:20
Check Details
使用曲美替尼你必须要了解的事情
2025-10-19 11:44:20
Check Details
国内已上市BRAF抑制剂:威罗非尼
2025-10-19 11:44:20
Check Details
威罗非尼适用于什么疾病?用法用量及副作用有哪些?
2025-10-19 11:44:20
Check Details
多食用富含膳食纤维的食物,有助于改善黑色素瘤的免疫治疗反应
2025-10-19 11:44:20
Check Details
达拉非尼也可用于治疗朗格汉斯组织细胞增生症
2025-10-19 11:44:20
Check Details
“抗癌神药”达拉非尼与威罗非尼联合治疗NSCLC
2025-10-19 11:44:20
Check Details
比美替尼在国内上市了吗?比美替尼可以医保报销吗
2025-10-19 11:44:20
Check Details
恩考芬尼联合比美替尼治疗转移性黑色素瘤
2025-10-19 11:44:20
Check Details
怎样才能买到曲美替尼Mekinist?曲美替尼的价格是多少
2025-10-19 11:44:20
Check Details
曲美替尼Mekinist的疗效好不好?治疗时要注意什么
2025-10-19 11:44:20
Check Details
威罗非尼(佐博伏)能延长黑色素瘤患者的生存期
2025-10-19 11:44:20
Check Details
1
2
...
679
680
681
682
683
684
685
...
4162
4163
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Ribociclib Still Allows Recurrence: HR+/HER2- Adjuvant and Advanced Use
2
Tucatinib HER2 TKI: With Trastuzumab + Capecitabine, Diarrhea and Hepatotoxicity Monitoring
3
Pemigatinib for FGFR2-Rearranged Cholangiocarcinoma: Eligibility, Response Limits, Hyperphosphatemia and Ocular Monitoring
4
Cabozantinib with Aspirin: Additive Bleeding Risk, Do Not Stop Cardiac Aspirin Alone, Urgent Warning Signs
5
Zongertinib for HER2-Mutant NSCLC: First-Line ORR About 76%, Brain Metastases Controlled, Manage Diarrhea and Hepatotoxicity
6
Selpercatinib Traditional Approval for RET Fusion Solid Tumors: Weight-Based Adults, BSA-Based Pediatrics, Monitor Liver, BP, QT
7
Atezolizumab Plus mFOLFOX as Adjuvant Therapy for Stage III dMMR Colon Cancer: ATOMIC DFS HR 0.50
8
Tucatinib Plus Trastuzumab and Pertuzumab Maintenance in HER2-Positive Advanced Breast Cancer: HER2CLIMB-05 Median PFS 24.9 Months
9
Zenocutuzumab (Bizengri) for NRG1 Fusion Solid Tumors: HER2×HER3 Bispecific, 750mg Q2W, NSCLC/Pancreas/Cholangiocarcinoma
10
Pemigatinib for FGFR2 Cholangiocarcinoma and FGFR1 Hematologic Use: First-Line Data, 21-Day Dosing, Phosphate and Ocular Management
11
Dabrafenib (Tafinlar) Complete Guide: Indications, Dosing, Combination Therapy and Safety
12
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma